Stock Events

Stock Events

VivoSim Labs 

$0.2787
86
-$0.01-4.36% 20:00 Today
+$0.01+3.66%21:47After hours

Statistics

Day High
0.2959
Day Low
0.2736
52W High
5.3
52W Low
0.26
Volume
360,566
Avg. Volume
5,626,171
Mkt Cap
3.73M
P/E Ratio
0.46
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-2.52
-2.36
-2.2
-2.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-10,567.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
131,000Revenue
-13.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VIVS. It's not an investment recommendation.
NVIDIA
7
NVDA
Microsoft
6
MSFT
Amazon
6
AMZN
SoundHound AI
6
SOUN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is involved in biopharmaceuticals and has investments in regenerative medicine and tissue engineering, competing in similar spaces as Organovo.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that engages in research and development in biotech and regenerative medicine, areas where Organovo also operates.
Merck
MRK
Mkt Cap366B
Merck operates in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Organovo's 3D bioprinting technologies.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific offers products and services in the life sciences field, including technologies that could compete with Organovo's bioprinting solutions.
Danaher
DHR
Mkt Cap151.89B
Danaher is a global science and technology innovator with businesses in life sciences and diagnostics, potentially competing with Organovo's offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on regenerative medicine and biotechnology, directly competing with Organovo's research and development in 3D bioprinting.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides genomics solutions, which could be used in conjunction with or in competition to Organovo's bioprinting technologies for personalized medicine.
Bio-Rad Laboratories
BIO
Mkt Cap10.37B
Bio-Rad Laboratories offers products and services in the life science research and clinical diagnostics markets, potentially competing with Organovo's technologies.
Stryker
SYK
Mkt Cap126.84B
Stryker is a medical technologies firm with products that could compete with Organovo's in areas such as surgical applications and regenerative medicine.

About

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Show more...
CEO
Keith Murphy
Employees
11
Country
United States
ISIN
US68620A3023
WKN
000A41083

Listings

XNAS
US
VIVS
F
DE
4OR.F
STU
DE
4OR.STU
MU
DE
4OR.MU

0 Comments

Share your thoughts

FAQ

What is VivoSim Labs stock price today?▼
The current price of VIVS is $0.28 USD — it has decreased by -4.36% in the past 24 hours. Watch VivoSim Labs stock price performance more closely on the chart.
What is VivoSim Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange VivoSim Labs stocks are traded under the ticker VIVS.
Is VivoSim Labs stock price growing?▼
VIVS stock has fallen by -4.42% compared to the previous week, the month change is a -19.12% fall, over the last year VivoSim Labs has showed a -88.58% decrease.
What is VivoSim Labs market cap?▼
Today VivoSim Labs has the market capitalization of 3.73M
When is the next VivoSim Labs earnings date?▼
VivoSim Labs is going to release the next earnings report on November 05, 2026.
What is VivoSim Labs revenue for the last year?▼
VivoSim Labs revenue for the last year amounts to 131,000 USD.
What is VivoSim Labs net income for the last year?▼
VIVS net income for the last year is -13.84M USD.
How many employees does VivoSim Labs have?▼
As of September 01, 2026, the company has 11 employees.
In which sector is VivoSim Labs located?▼
VivoSim Labs operates in the Health & Wellness sector.
When did VivoSim Labs complete a stock split?▼
The last stock split for VivoSim Labs was on March 21, 2025 with a ratio of 1:12.
Where is VivoSim Labs headquartered?▼
VivoSim Labs is headquartered in SAN DIEGO, United States.